A fatty liver drug from Gilead Sciences posts negative results in late-stage clinical trial

A readout from the first late-stage clinical trial intended to treat the fatty liver disease known as NASH has delivered disappointing results.

Gilead Sciences said Monday that its experimental drug, called selonsertib, failed